Clinical Trial Detail

NCT ID NCT01736943
Title Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, Davis
Indications

acute myeloid leukemia

Therapies

Bortezomib + Pegylated liposomal-doxorubicin

Age Groups: adult

No variant requirements are available.